| Symbol | BBOT |
|---|---|
| Name | BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | C/O CORMORANT ASSET MANAGEMENT, LP,200 CLARENDON STREET,52ND FLOOR, BOSTON, Massachusetts, 02116, United States |
| Telephone | 857 702 0377 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, visit bbotx.com. Additional info from NASDAQ: |
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
Read moreBBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
Read moreBBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
Read moreBBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Read moreBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Read moreLebowitz Peter F 🟢 acquired 63.4K shares (1 derivative) of BridgeBio Oncology Therapeutics, Inc. (BBOT) at $8.72 Transaction Date: Mar 24, 2026 | Filing ID: 126602
Read more(99% Neutral) BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. (BBOT) Announces New Board Appointment
Read moreNew Form 3 - BridgeBio Oncology Therapeutics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001193125-26-126590 <b>Size:</b> 26 KB
Read moreNew Form 424B3 - BridgeBio Oncology Therapeutics, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0001193125-26-126508 <b>Size:</b> 24 KB
Read moreBBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Read more